Evidence map›Paper›PMID 28444847›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2017

Complement Dependence of Murine Costimulatory Blockade-Resistant Cellular Cardiac Allograft Rejection.

N Chun, R L Fairchild, Y Li, J Liu, M Zhang, W M Baldwin, P S Heeger

Abstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Back-table intra-arterial administration of C1 esterase inhibitor to deceased donor kidney allografts improves posttransplant allograft function: Results of a randomized double-blind placebo-controlled clinical trial.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025
    Trial
  2. Therapeutic Potential of C1-Inhibitor in Vascular Diseases and Beyond.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  3. Article
  4. Review
  5. Exosome-primed T cell immunity is facilitated by complement activation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  6. Complement and T cell activation in transplantation.Transplantation reviews (Orlando, Fla.) · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2021
    Article
  15. Article
  16. Review
  17. Sterile inflammation in thoracic transplantation.Cellular and molecular life sciences : CMLS · 2021
    Review
  18. Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Article
  19. Review
  20. A case for the reuse and adaptation of mechanistic computational models to study transplant immunology.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

N ChunDepartment of Medicine, Translational Transplant Research Center, Recanati Miller Transplant Institute, Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
R L FairchildDepartment of Immunology, Cleveland Clinic, Cleveland, OH.
Y LiDepartment of Medicine, Translational Transplant Research Center, Recanati Miller Transplant Institute, Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
J LiuDepartment of Medicine, Translational Transplant Research Center, Recanati Miller Transplant Institute, Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
M ZhangSUNY Downstate Medical Center, Brooklyn, NY.
W M BaldwinDepartment of Immunology, Cleveland Clinic, Cleveland, OH.
P S HeegerDepartment of Medicine, Translational Transplant Research Center, Recanati Miller Transplant Institute, Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Funding

Surgery CoreP01AI087586 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI VALUJSKIKH, ANNA · 2010 to 2019
$17.2M
POSTTRANSPLANT INFLAMMATORY RESPONSER01AI040459 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI Robert L Fairchild · 1997 to 2026
$9.4M
Translational Immunology Training ProgramT32AI078892 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Karen Leigh Edelblum, SERGIO A. LIRA · 2008 to 2026
$4.5M
Complement & T Cell Medicated Allograft RejectionR01AI071185 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEEGER, PETER SCOTT · 2007 to 2016
$4.3M
Mount Sinai Nephrology Research Training GrantT32DK007757 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI CAMPBELL, KIRK N, HE, JOHN CIJIANG · 1998 to 2022
$3.8M
Cell Death Pathways and Heart Transplant RejectionR01AI132405 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEEGER, PETER SCOTT, TING, ADRIAN T · 2017 to 2021
$2.8M
Targeting factor B to prevent transplant rejectionR21AI117695 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI HEEGER, PETER SCOTT, ZHANG, MING · 2015 to 2016
$480k
NIAID NIH HHS P01 AI087586NIAID NIH HHS R01 AI040459NIAID NIH HHS R01 AI071185NIAID NIH HHS R01 AI132405NIAID NIH HHS R21 AI117695NIAID NIH HHS T32 AI078892NIDDK NIH HHS T32 DK007757
6 · The paper itself

Abstract

Building on studies showing that ischemia-reperfusion-(I/R)-injury is complement dependent, we tested links among complement activation, transplantation-associated I/R injury, and murine cardiac allograft rejection. We transplanted BALB/c hearts subjected to 8-h cold ischemic storage (CIS) into cytotoxic T-lymphocyte associated protein 4 (CTLA4)Ig-treated wild-type (WT) or c3

Indexed as

AbataceptAllograftsAnimalsComplement System ProteinsCTLA-4 AntigenGraft RejectionGraft SurvivalHeart TransplantationImmunosuppressive AgentsMaleMiceMice, Inbred BALB CMice, Inbred C57BLTissue DonorsT-LymphocytesAbataceptComplement System ProteinsCTLA-4 AntigenCTLA4 protein, humanImmunosuppressive Agentsanimal models: murinebasic (laboratory) research/sciencecomplement biologycostimulationimmunobiologyimmunosuppression/immune modulation

Identifiers

PMID28444847
PMCPMC5912159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.